Company Analysis Arrowhead Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (18.49 $) is less than fair price (37.86 $)
Disadvantages
- Dividends (0%) are below the sector average (1.31%).
- The stock's return over the last year (-37.88%) is lower than the sector average (-0.7555%).
- Current debt level 44.79% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-262.48%) is lower than the sector average (ROE=-80.86%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Arrowhead Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 6.1% | 2.4% | -0.4% |
| 90 days | 3.3% | -4.9% | 1.5% |
| 1 year | -37.9% | -0.8% | 21.8% |
ARWR vs Sector: Arrowhead Pharmaceuticals, Inc. has significantly underperformed the "Healthcare" sector by -37.13% over the past year.
ARWR vs Market: Arrowhead Pharmaceuticals, Inc. has significantly underperformed the market by -59.66% over the past year.
Stable price: ARWR is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ARWR with weekly volatility of -0.7285% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (18.49 $) is lower than the fair price (37.86 $).
Price significantly below the fair price: The current price (18.49 $) is 104.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (478.56) is higher than that of the sector as a whole (57.87).
P/E vs Market: The company's P/E (478.56) is higher than that of the market as a whole (47.68).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (12.14) is higher than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (12.14) is lower than that of the market as a whole (22.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (653.4) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (653.4) is higher than that of the market as a whole (15.21).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.86) is lower than that of the sector as a whole (17.62).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.86) is lower than that of the market as a whole (24.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 121.72% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (121.72%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-66.62%).
5.4. ROE
ROE vs Sector: The company's ROE (-262.48%) is lower than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (-262.48%) is lower than that of the market as a whole (18.08%).
5.5. ROA
ROA vs Sector: The company's ROA (-62.93%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (-62.93%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.31%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 2264.69% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 23.01.2025 | OLUKOTUN ADEOYE Y Director |
Sale | 21 | 20 139 | 959 |
| 02.01.2025 | Anzalone Christopher Richard Chief Executive Officer |
Sale | 19.05 | 219 456 | 11 520 |
| 27.12.2024 | OLUKOTUN ADEOYE Y Director |
Purchase | 19.99 | 56 972 | 2 850 |
| 18.12.2024 | Anzalone Christopher Richard Chief Executive Officer |
Sale | 21.24 | 567 363 | 26 712 |
| 17.12.2024 | GIVEN DOUGLAS B Director |
Sale | 22.04 | 12 056 | 547 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
